Macquarie Group
CLSD

Macquarie Group’s Clearside Biomedical CLSD Stock Holding History

Macquarie Group’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-278
Closed -$4K – 1891
2019
Q2 		$4K Buy
+278
New +$4.96K ﹤0.01% 1817
2019
Q1 		– Sell
-360
Closed -$6K – 1705
2018
Q4 		$6K Buy
+360
New +$16.9K ﹤0.01% 2041

Other funds holding CLSD

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

Macquarie Group's CLSD Position: Q3 2019 in Review

Macquarie Group sold out of Clearside Biomedical (CLSD) in Q3 2019, closing a stake of 278 shares — an estimated $4K sold.

Macquarie Group first reported a position in CLSD in Q4 2018 and held it in 2 quarters. The position peaked at $6K in Q4 2018. 34 funds tracked by Wall St. Rank hold CLSD as of Q3 2019.

  • Macquarie Group reported no remaining Clearside Biomedical position as of Q3 2019 after selling out during the quarter.
  • Macquarie Group sold 278 Clearside Biomedical shares in Q3 2019, an estimated $4K.
  • Macquarie Group first reported a position in Clearside Biomedical in Q4 2018 and held it in 2 quarters.
  • Macquarie Group's Clearside Biomedical position peaked at $6K in Q4 2018.
  • 34 funds tracked by Wall St. Rank held Clearside Biomedical as of Q3 2019.

Based on Macquarie Group's 13F filing for Q3 2019, filed 14 Nov 2019.